



# The Human-Specific and Smooth Muscle Cell-Enriched LncRNA SMILR Promotes Proliferation by Regulating Mitotic CENPF mRNA and Drives Cell-Cycle Progression Which Can Be Targeted to Limit Vascular Remodeling

Amira D. Mahmoud\*, Margaret D. Ballantyne\*, Vladislav Miscianinov, Karine Pinel, John Hung, Jessica P. Scanlon, Jean Iyinkkel, Jakub Kaczynski, Adriana S. Tavares, Angela C. Bradshaw, Nicholas L. Mills, David E. Newby, Andrea Caporali, Gwyn W. Gould, Sarah J. George, Igor Ulitsky, Judith C. Sluimer, Julie Rodor, Andrew H. Baker

**RATIONALE:** In response to blood vessel wall injury, aberrant proliferation of vascular smooth muscle cells (SMCs) causes pathological remodeling. However, the controlling mechanisms are not completely understood.

**OBJECTIVE:** We recently showed that the human long noncoding RNA, SMILR, promotes vascular SMCs proliferation by a hitherto unknown mechanism. Here, we assess the therapeutic potential of SMILR inhibition and detail the molecular mechanism of action.

**METHODS AND RESULTS:** We used deep RNA-sequencing of human saphenous vein SMCs stimulated with IL (interleukin)-1 $\alpha$  and PDGF (platelet-derived growth factor)-BB with SMILR knockdown (siRNA) or overexpression (lentivirus), to identify SMILR-regulated genes. This revealed a SMILR-dependent network essential for cell cycle progression. In particular, we found using the fluorescent ubiquitination-based cell cycle indicator viral system that SMILR regulates the late mitotic phase of the cell cycle and cytokinesis with SMILR knockdown resulting in  $\approx 10\%$  increase in binucleated cells. SMILR pulldowns further revealed its potential molecular mechanism, which involves an interaction with the mRNA of the late mitotic protein CENPF (centromere protein F) and the regulatory Staufen1 RNA-binding protein. SMILR and this downstream axis were also found to be activated in the human ex vivo vein graft pathological model and in primary human coronary artery SMCs and atherosclerotic plaques obtained at carotid endarterectomy. Finally, to assess the therapeutic potential of SMILR, we used a novel siRNA approach in the ex vivo vein graft model (within the 30 minutes clinical time frame that would occur between harvest and implant) to assess the reduction of proliferation by EdU incorporation. SMILR knockdown led to a marked decrease in proliferation from  $\approx 29\%$  in controls to  $\approx 5\%$  with SMILR depletion.

**CONCLUSIONS:** Collectively, we demonstrate that SMILR is a critical mediator of vascular SMC proliferation via direct regulation of mitotic progression. Our data further reveal a potential SMILR-targeting intervention to limit atherogenesis and adverse vascular remodeling.

**VISUAL OVERVIEW:** An online [visual overview](#) is available for this article.

**Key Words:** blood vessels ■ cell cycle ■ growth factors ■ interleukins ■ muscle cells ■ noncoding RNA ■ saphenous vein

**In This Issue, see p 503 | Meet the First Author, see p 504**

Correspondence to: Andrew H. Baker, BSc (Hons), PhD, University of Edinburgh, BHF Centre for Cardiovascular Sciences, Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, United Kingdom. Email [andy.baker@ed.ac.uk](mailto:andy.baker@ed.ac.uk)

\*A.D.M. and M.D.B. contributed equally to this article.

The online-only Data Supplement is available with this article at <https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.119.314876>.

For Sources of Funding and Disclosures, see page 550.

© 2019 The Authors. *Circulation Research* is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the [Creative Commons Attribution](#) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.

*Circulation Research* is available at [www.ahajournals.org/journal/res](http://www.ahajournals.org/journal/res)

## Novelty and Significance

### What Is Known?

- Like other noncoding RNA, long noncoding RNA (lncRNA) can regulate key aspects of smooth muscle cell function.
- LncRNA SMILR regulates smooth muscle cell proliferation via an unknown mechanism.

### What New Information Does This Article Contribute?

- LncRNA SMILR regulates a network of cell cycle-associated mRNAs in vascular smooth muscle cells.
- LncRNA SMILR binds directly to the mitotic cell regulator CENPF (centromere protein F) mRNA.
- Inhibition of SMILR by RNA interference blocks vascular smooth muscle cell proliferation in intact saphenous vein.

Vascular smooth muscle cell proliferation has been recognized as central to the pathology of many major forms of vascular disease including intimal hyperplasia associated with vein graft failure. Previously, RNA-sequencing

identified SMILR as a novel intergenic lncRNA activated by vascular smooth muscle cell proliferation. Understanding the molecular mechanisms governing the mode of action of SMILR is an important next step. Specific modulation of SMILR levels revealed its role in regulating a mitotic mRNA network and more specifically a central role for binding to the cell cycle-associated CENPF mRNA. Specific knockdown of SMILR resulted in the accumulation of binucleated cells and reduced proliferation and was phenotypically copied by silencing of CENPF. Furthermore, we show that SMILR binds the RNA-binding protein Stau1 (Staufen 1), which may aid in the regulation of cell cycle. Finally, SMILR inhibition in whole vein segments resulted in the reduction of smooth muscle cell proliferation through modulation of the key cell cycle network. Our findings provide compelling evidence that SMILR is a novel target in the treatment of aberrant growth of vascular smooth muscle cells.

## Nonstandard Abbreviations and Acronyms

<b>AurKB</b>	aurora kinase N
<b>CENPF</b>	centromere protein F
<b>FACS</b>	fluorescence-activated cell sorter
<b>FUCCI</b>	fluorescence ubiquitin cell cycle indicator
<b>GFP</b>	green fluorescent protein
<b>HCASMCs</b>	human coronary artery smooth muscle cells
<b>HSV</b>	human saphenous vein
<b>HSVSMCs</b>	humans saphenous vein derived smooth muscle cells
<b>IL</b>	interleukin
<b>IL1-PDGF</b>	IL-1 $\alpha$ and PDGF- $\beta\beta$ -induced
<b>lncRNA</b>	long noncoding RNA
<b>PDGF</b>	platelet-derived growth factor
<b>qRT-PCR</b>	quantitative real-time polymerase chain reaction
<b>RAP</b>	RNA antisense pulldown
<b>RNA-seq</b>	RNA-sequencing
<b>siRNA</b>	small interfering RNA
<b>STAU1</b>	Staufen 1
<b>UBC</b>	ubiquitin C
<b>vSMCs</b>	vascular smooth muscle cells

**A** aberrant proliferation of vascular smooth muscle cells (vSMCs) is a common and functionally important mechanism that impacts on the pathogenesis of many vascular diseases, including intimal thickening associated

with remodeling of intravascular stents, coronary artery bypass graft failure, atherosclerosis, and aortic aneurysm formation. In particular, vSMC proliferation is promoted by the injurious microenvironment, partly through the increased exposure of vSMC to inflammatory cytokines and growth factors such as IL (interleukin)-1 and PDGF (platelet-derived growth factor), respectively. These often act in synergy to promote a proliferative phenotype with associated activation of critical gene networks, such as metalloproteinases.<sup>1–4</sup> Clinically, targeting vSMC proliferation is exceptionally effective at reducing adverse vascular remodeling following balloon angioplasty and vessel stenting, evidenced by extensive research and development of antiproliferative drug-eluting stent technologies.<sup>5,6</sup> For iatrogenic vascular injury, pathogenic SMC proliferation causes intimal hyperplasia and luminal narrowing of blood vessels in the setting of vascular stenting or vein graft failure.<sup>2,7</sup> In more complex settings, such as atherosclerosis, vSMC proliferation is central to the accumulation of large numbers of plaque-derived vSMC that not only contribute to the atherogenic process itself but can also confer plaque stabilization.<sup>8,9</sup> Despite context-dependent heterogeneity in vSMC pathobiology, the underlying activation of vSMC proliferation is a central phenotype to the progression of vessel wall dysfunction. It is, therefore, imperative to further understand the molecular mechanisms that govern vSMC proliferation pathways to advance innovative therapies.

Recently, robust evidence has revealed that noncoding RNAs may play a vital role in the regulation of tissue homeostasis, including cardiovascular homeostasis, and hence pathophysiological conditions.<sup>10</sup> Mammalian genomes are pervasively transcribed to produce thousands of long

noncoding RNAs (lncRNAs). LncRNAs are widely involved in physiological and pathological processes, such as cancer,<sup>11</sup> autoimmune diseases,<sup>12</sup> and cardiac disease.<sup>13</sup> LncRNA can exert their function via a broad range of activities including, but not limited to, chromatin remodeling, formation of nuclear bodies, and activities as scaffolds and guides.<sup>14</sup> Previous findings have suggested that a substantial proportion of lncRNAs reside within, or are dynamically shuttled to, the cytoplasm to regulate mRNA stability, protein translation, microRNA availability, and impact on protein modifications.<sup>15</sup> Such RNA-based regulation generally relies on lncRNA interactions with RNA-binding proteins.<sup>16</sup> We previously identified the lncRNA SMILR by RNA-sequencing (RNA-seq) of human vSMCs following activation by IL-1 $\alpha$  and PDGF- $\beta\beta$  signaling.<sup>17</sup> SMILR is an intergenic and poorly conserved lncRNA that consists of only a single 3-exon polyadenylated transcript that is vSMC-enriched, and its knockdown by RNA interference blocked IL-1 $\alpha$  and PDGF- $\beta\beta$ -induced (IL1-PDGF) vSMC proliferation.<sup>17</sup> Thus, we reasoned that identifying the downstream targets and binding partners of SMILR would reveal the specific mechanism by which it regulates vSMC proliferation and hence provide a novel therapeutic target for preventing adverse vascular remodeling.

## METHODS

The authors declare that all supporting data and materials are available within the article (and its in the [Online Data Supplement](#)) and available from the corresponding author on reasonable request. All RNA-seq data have been made deposited in the Gene Expression Omnibus repository, study number GSE120521 for the atherosclerosis RNA-seq and GSE117608 for SMILR RNA-seq.

Expanded information about materials and methods are available in the [Online Data Supplement](#).

## Declaration of Helsinki

All studies comply with the Declaration of Helsinki, that the locally appointed ethics committee has approved the research protocol and that informed consent has been obtained from the subjects.

Primary human saphenous vein SMCs (HSVSMCs) were isolated via explant technique from consented patients and cultured as previously described.<sup>17</sup> All procedures had local ethical approval (15/ES/0094). HSVSMCs from passage 3 to 5 were used for this study, and cells were synchronized in DMEM containing 0.2% FBS for 48 hours before experimentation. Modulation of SMILR expression was performed through the utilization of dsRNA or SMILR lentivirus with appropriate controls and their effect on the genome was assessed via RNA-seq and confirmed through subsequent quantitative real-time polymerase chain reaction (qRT-PCR) validation. All qRT-PCR data were analyzed via the  $2^{-\Delta\Delta C_t}$  method.<sup>18</sup> This method uses a house keeping gene and UBC (ubiquitin C) was selected as a housekeeping gene due to its stability across all groups and conditions studied. Data are graphed as relative quantification normalized to the UBC housekeeping gene.<sup>18</sup>

Assessment of siRNA-SMILR on SMC cell cycle was performed via fluorescence ubiquitin cell cycle indicator (FUCCI)-fluorescence-activated cell sorter (FACS) analysis and confocal imaging for the percent of binucleated cells. siRNA targeting AURKB was used as a positive control in these studies as previously described.<sup>19,20</sup>

To evaluate binding partners of SMILR, antisense SMILR, or GFP (green fluorescent protein) probes were designed. For each pulldown experiment, either 5 GFP or 5 SMILR probes were used to capture bound RNA. Before RNA extraction, RNA was spiked with 75 ng of total *Caenorhabditis elegans* RNA and AMA1 used as a reference gene as previously described.<sup>21</sup> qRT-PCR was used to assess RNA expression.

To assess if SMILR exhibited any venous/arterial differences in expression or function, human coronary artery SMCs (HCASMC) were used and cultured under the same conditions as HSVSMCs. Stimulation of these cells was performed under basal and IL-1/PDGF-BB stimulated conditions as described in Ballantyne et al<sup>17</sup> and assessment of the effect of siRNA-SMILR on HCASMC proliferation (Edu-FACS), binucleation (confocal imaging), and downstream target expression (qRT-PCR) was performed.

To address if SMILR exhibited any protein binding partners, SMILR protein pulldowns were performed using streptavidin magnetic beads to capture the biotinylated RNA target and any bound proteins from stimulated SMCs. Mass spectrometric analysis was used to identify proteins for subsequent downstream analysis and validation. Anti-Stau1 (Staufen 1) pulldowns were used as validation with appropriate IgG control to confirm SMILR and other RNA target binding by qRT-PCR.

Similar to Ballantyne et al<sup>17</sup> patients with symptomatic carotid artery stenosis scheduled to undergo carotid endarterectomy were recruited from neurovascular clinics at the Royal Infirmary of Edinburgh to undergo separate [18F]-fluoride and [18F]-fluorodeoxyglucose positron emission tomography combined with computed tomography scans. Regions of stable and unstable plaque were denoted by low and high tracer uptake respectively and appropriately dissected. RNA-seq was performed to assess transcriptomic differences between plaque sections and SMILR expression assessed via qRT-PCR. In situ hybridization was used to visualize the localization of SMILR within the plaque regions.

To assess the potential clinical utilization of siSMILR, segments of human saphenous vein obtained from consented patients undergoing bypass surgery were pinned down with minuten pins on a Sylgard coated dissection dish with the luminal surface facing upward for 0, 7, or 14 days with media refreshed every 2 days. At day 0 and after 7 and 14 days of culture, the vein segments were washed in PBS and snap-frozen for subsequent RNA extraction or fixed in 4% PFA for histology. Proliferation of segments was assessed through the utilization of Click-iT Edu Alexa Fluor 488 In Vivo Imaging Kit. Expression levels of SMILR and target RNA were assessed through qRT-PCR analysis. For siRNA transfections, HSV segments cut in equal pieces of  $\approx 1$  cm<sup>2</sup> were bathed in PBS containing 25  $\mu$ mol/L siSMILR and scrambled siRNA control for 30 minutes in 24-well plate. After 30 minutes of incubation, the vein segments were washed with PBS and pinned down as described above. To confirm siRNA transfection, cy3-tagged SMILR was transfected and visualized along with DAPI (4',6-diamidino-2-phenylindole) and  $\alpha$ -smooth muscle actin costaining via confocal imaging.

Samples of  $\geq n=5$  were subjected to the Shapiro-Wilk test to assess normal distribution followed by Student *t* test or

ANOVA. Normal distribution cannot be determined on small samples sizes and samples with  $n < 5$  were assumed to be not normally distributed and subjected to Iman and Conover nonparametric ranking followed by Student *t* test or ANOVA. Statistical significance  $P < 0.05$  under all conditions.

## RESULTS

### Manipulation of SMILR Expression Identifies a Target Cell Cycle Network in HSVSMCs

SMILR depletion and overexpression were previously shown to decrease and increase, respectively, proliferation induced by stimulation of HSVSMCs with IL1-PDGF.<sup>17</sup> However, no characterization of the mechanisms of regulation of SMILR by IL1-PDGF was described. Accordingly, we sought to identify the potential transcription factor binding sites within the promoter region of SMILR (Online Figure IA). Within the 2000 bp upstream of SMILR's transcription start site, we identified binding sites for transcription factors that are activated by IL-1 $\alpha$  and PDGF-BB, including NF- $\kappa$ B (nuclear factor kappa-light-chain-enhancer of activated B cells), CEBP- $\beta$  (CCAAT enhancer-binding protein beta), ETS1 (ETS proto-oncogene 1), AP1 (activator protein 1), NFAT (nuclear factor of activated T cells), IRF8 (interferon regulatory factor 8), MYB (MYB proto-oncogene), and AML (acute myeloid leukemia 1; Online Figure IB). Of the commercially available transcription factor inhibitors, we analyzed the subsequent effects on SMILR expression following IL1-PDGF stimulation. This identified that the upregulation of SMILR following IL1-PDGF stimulation may, in part, be because of activation of NF- $\kappa$ B (Online Figure IC and controls in Online Figure ID). Interestingly, SMILR overexpression does not trigger quiescent HSVSMCs to proliferate in the absence of IL1-PDGF stimulation (Online Figure II). Therefore, to further determine the downstream effects of manipulation of SMILR levels on proliferation, RNA-seq was performed on stimulated HSVSMCs exposed to either SMILR depletion via siRNA (siSMILR) or overexpression via lentivirus treatment to identify a downstream SMILR-dependent transcriptome (Figure 1A).

Quantification of miR-146a, -221 and -222 by qRT-PCR confirmed activation of the IL-1 $\alpha$  and PDGF- $\beta$  signaling pathways, respectively (Online Figure III).<sup>22,23</sup> Alterations in SMILR expression levels were validated by qPCR (Figure 1B). Considering a fold change  $\geq 1.5$  and an adjusted false discovery rate  $P < 0.05$ , 523 (334 downregulated and 189 upregulated) and 183 (126 upregulated and 57 downregulated) transcripts were significantly differentially expressed following knockdown or overexpression, respectively (Figure 1C). As we observe opposing effects on proliferation with SMILR knockdown and overexpression, we focused on the transcripts that were dysregulated in opposing levels. This revealed 68 transcripts (Figure 1C and 1D) indicating that such an approach might be powerful in identifying a distinct SMILR-targeted

biological interactome. This set of SMILR-regulated genes was enriched for cell division-related and nucleosome assembly gene ontology terms (Figure 1E). Interestingly, analysis by STRING (Search Tool for the Retrieval of Interacting Genes/Proteins)<sup>24</sup> identified that 59% ( $n = 40$  of 68 genes) of the overlapping genes were associated with a single network involved in progression through the cell cycle, primarily the mitotic phase (Figure 1F). The top 20 genes identified by RNA-seq that were differentially regulated genes by SMILR (Online Figure IV) were selected for further validation in 3 different patient saphenous vein derived SMCs by qRT-PCR. We observed consistent and robust opposing regulation of the network following SMILR depletion and overexpression in HSVSMCs stimulated with IL1-PDGF (Figure 1G and 1H). In agreement with the absence of proliferation phenotype after SMILR overexpression in nonstimulated quiescent conditions, SMILR overexpression in nonstimulated quiescent HSVSMCs did not result in transcription changes of the identified network (Online Figure IIB). Collectively, these data suggest that SMILR mechanistically targets the vSMC cell cycle in response to IL1-PDGF stimulation.

### Manipulation of SMILR Expression Effects Cell Cycle Progression in vSMC

Next, we functionally assessed SMILR's ability to directly target cell cycle progression in HSVSMCs. First, we used the FUCCI viral system as well as flow cytometric analysis to track the cell cycle in synchronized HSVSMCs stimulated with IL1-PDGF for 96 hours with and without SMILR knockdown. After FUCCI viral infection, cells in G0/G1 and S/G2/early M cell cycle phases express mCherry and mAzami-Green, respectively.<sup>25</sup> Figure 2A represents the color change predicted in cycling cells, dependent on the relative stage of cell cycle—red (G1), yellow/orange (G1/S), green (G2/early M), or colorless (late M/G0) fluorescence. AurKB (aurora kinase B), a well-known cell cycle and mitotic mediator, was used as a positive control. Notably, it is also one of SMILR's downstream targets in the interactome (Figure 1F). Consistent with previous findings showing IL1-PDGF stimulation only promotes 30% of quiescent cells to proliferate,<sup>17</sup>  $\approx 60\%$  of the FUCCI-infected HSVSMCs stimulated with IL1-PDGF were found to be colorless under control conditions (Figure 2B and 2C). Effective knockdown of AurKB in the HSVSMCs ( $4 \pm 0.48$ -fold reduction compared to control; Online Figure V) resulted in a cell cycle defect with a decrease in the G1 phase ( $P < 0.05$ ) and concurrent increase in M/G0 phase ( $P < 0.05$ ; Figure 2B and 2C). Analysis on FUCCI-infected cells also revealed a clear defect in the G1 phase and increase in the late M/G0 phase of the cell cycle following treatment with siSMILR, thereby phenocopying the effect of AurKB knockdown (Figure 2C). A hallmark of such a mitotic phase defect is the inability to correctly segregate





daughter from mother cells during cytokinesis, resulting in cellular binucleation,<sup>26</sup> which was evident in both FUCCI-infected cells treated with siAurKB and siSMILR (Figure 2D). Accordingly, cells treated with siSMILR and siAURKB were stained with DAPI and phalloidin and assessed for binucleation via fluorescent microscopy (Figure 2E and 2F). This revealed an increase in the percentage of binucleated cells from  $7.2 \pm 0.6\%$  and  $9.1 \pm 0.3\%$  in nontransfected and siControls, respectively, to  $17.1 \pm 0.4\%$  following SMILR depletion ( $P < 0.05$ ), and a similar phenotype was observed in siAurKB-treated cells ( $20.3 \pm 1.6\%$  binucleation; Figure 2G). Importantly, siRNA treatment had no significant effect on apoptosis with any of the siRNA-based treatments (Figure 2H). Taken together, these data implicate a function for SMILR in regulating the late mitotic phase of cell cycle in vSMCs.

### SMILR Directly Targets CENPF in the Cell Cycle Network

With both overexpression<sup>17</sup> and knockdown (Online Figure IV) approaches affecting SMILR expression levels predominantly in the cytoplasmic fraction, we, therefore, reasoned that SMILR could directly regulate the identified affected genes by binding to the mRNA in the cytoplasm. We used a database of predicted lncRNA-RNA interactions by Terai et al<sup>27</sup> and considered the top 100 genes predicted to interact with SMILR based on SumEnergy (Online Table I). These genes were analyzed in terms of expression level in stimulated vSMC, differential expression in SMILR depleted or SMILR overexpressed conditions, as well as differential expression on stimulation with IL1-PDGF (see filtering details in [Online Data Supplement](#) methods and summary in Online Table I). This revealed that CENPF, a mitotic centromere protein, was the highest-ranked mRNA predicted to interact with SMILR (minimum and sum energy of  $-35$  and  $-2631$  kcal/mol, respectively, Online Table I). The predicted interacting base pair region of the SMILR/CENPF mRNA interaction extends across 51 base pairs (39–90) within the sequence of SMILR and 58 base pairs (3291–3349) within the coding sequence of CENPF transcript (Online Figure VII). We used RNA antisense pulldown followed by qRT-PCR to confirm this predicted interaction. Two sets (5 even and 5 odd) of 3'-biotinylated DNA capture oligonucleotides were designed to hybridize specifically to SMILR (Online Data Supplement).<sup>28,29</sup> One set of 5 GFP-specific 3'-biotinylated DNA capture oligonucleotides were also used as a negative control. A schematic overview of the experimental design is provided in Figure 3A. The


relative enrichment of SMILR and the CENPF mRNA present in both the SMILR-even and -odd pools was calculated with respect to the GFP pool, which was used as background reference. We observed a 3- and 4-fold enrichment of SMILR with the even and odd probes, respectively. CENPF transcript was also coenriched by 13- and 7-fold in the even and odd SMILR pulldowns, respectively, thereby independently validating the predicted interaction between SMILR and CENPF mRNA. Importantly, MKI67 (marker of proliferation Ki-67) mRNA another downstream target within the SMILR-dependent cell cycle network was assessed in the even and odd SMILR pulldowns and found to not to be enriched—suggesting specificity for a SMILR:CENPF mRNA interaction within the interactome (Figure 3B). Additionally, in agreement with the RNA-seq data, SMILR depletion and overexpression led to a downregulation and upregulation of CENPF transcript levels, respectively (Figure 3C and 3D). While having no effect on apoptosis, CENPF depletion (Online Figure VIII) resulted in a significant decrease in EdU incorporation (Figure 3E and 3F). Additionally, similar to previous findings,<sup>30,31</sup> CENPF depletion resulted in an increase in the percentage of binucleated cells ( $12.5 \pm 1.2\%$ ) comparable to SMILR knockdown ( $13.7 \pm 2.2\%$ ), which was significantly greater than that observed under control conditions ( $6.0 \pm 2.0\%$ ,  $P < 0.05$ , Figure 3G and 3H). Importantly, knockdown of CENPF also phenotypically mimics the effects of SMILR knockdown on key genes within the cell cycle network (Figure 3I). Thus, these data support the concept that SMILR positively targets CENPF mRNA, which is critical for vSMC proliferation.

To further examine the temporal involvement of SMILR and CENPF transcripts in promoting IL1-PDGF induced proliferation, time-course experiments were used and show that SMILR expression is significantly upregulated before significant EdU+ incorporation and CENPF mRNA expression is detected (Online Figure IX). Taken together, this suggests that SMILR is required at the early stages of IL1-PDGF stimulation to promote the induction of proliferation and mitotic progression.

### The SMILR:CENPF RNA Interaction Is Regulated by Staufen1

RNAs, including lncRNAs, have been found to occasionally contain structural motifs that can interact with other RNAs to form functional RNA-RNA hybrids, which can then recruit proteins that regulate their function or stability.<sup>32</sup> Accordingly, to understand whether the function of SMILR/CENPF RNA hybrid is dependent on an

**Figure 1 Continued. G and H,** Further validation by qRT-PCR of the top 20 identified dysregulated proliferative and cell cycle-associated genes with siRNA control (siCtrl) vs siSMILR and control LNT (null LNT) vs SMILR LNT. IL indicates interleukin; MOI, multiplicity of infection; and PDGF, platelet-derived growth factor. \* $P < 0.05$ , by 1-man and Conover nonparametric ranked paired Student *t* test of deltaCT values between gene of interest and the housekeeper gene UBC (ubiquitin C), n=3 biological replicates.



**Figure 2. SMILR manipulation regulates the cell cycle of vascular smooth muscle cells (vSMC).**

**A**, Schematic of fluorescence ubiquitin cell cycle indicator (FUCCI) viral analysis. **B**, Flow cytometric analysis tracking cell cycle changes indicated by color changes of the FUCCI viruses. **C**, Bar chart representing average changes in the % of cells in each stage of the cell cycle. Repeated measures ANOVA for  $*P < 0.05$ , Iman and Conover ranked nonparametric analysis followed by 1-way ANOVA,  $n = 3$  biological replicates. **D**, Fluorescent microscopy of humans saphenous vein derived smooth muscle cells (HSVSMCs) infected with the FUCCI viral system. Scale bars at 50 µm. Red arrows indicate binucleated cells. **E**, Schematic of characterization method of binucleated cells. **F**, Fluorescent images of HSVSMCs stained with DAPI (4',6-diamidino-2-phenylindole) and phalloidin. Scale bars at 50 µm. Red arrows indicate binucleated cells. (Continued)



RNA:protein binding interaction, we performed pulldowns using 3'-desthiobiotin-labeled full-length SMILR and protein lysates from IL1-PDGF stimulated HSVSMCs (Figure 4A). Mass spectrometry identified 14 potential SMILR-binding proteins (Figure 4B). The STAU1, known to be involved in mRNA decay and binds lncRNA and mRNA hybrids,<sup>33</sup> was clearly enriched in SMILR pulldowns when compared with beads alone or control 3'-desthiobiotin-labeled full-length GFP pulldowns (Online Figure X). Moreover, previous reports have suggested that STAU1 is involved in checkpoint decisions in G2 and/or G2/M transitions, which intersects with the cell cycle defects observed with siSMILR.<sup>34</sup> Hence, STAU1 seems to be a prime candidate partner for SMILR's mechanism of action. Immunoprecipitation of STAU1 from HSVSMC lysates stimulated with IL-1 PDGF followed by qRT-PCR revealed enrichment of SMILR by  $2.8 \pm 1$ -fold ( $P < 0.05$ ) when compared with IgG controls (Figure 4C), validating the mass spectrometry results. Additionally, we found that STAU1 is likely to bind to SMILR within the first half of its sequence, which as mentioned above, is the predicted interaction site with CENPF (Online Figures VII and XI). We also identified coenrichment of CENPF in the STAU1 pulldowns by  $5.0 \pm 2.2$ -fold ( $P < 0.05$ ; Figure 4C). To explore the involvement of STAU1 in controlling the proliferative phenotype mediated by SMILR and CENPF, we knocked down STAU1 using dsRNA and revealed an increase of SMILR and CENPF mRNA by  $3.3 \pm 0.9$ - and  $3.0 \pm 1.1$ -fold, respectively (Figure 4D). We accordingly sought to further examine the effect of STAU1 knockdown on the SMILR downstream targets. Analysis of the same 20 targets described in Figure 1, which are downregulated and upregulated following SMILR knockdown and overexpression, revealed that 7 of these genes were significantly upregulated with STAU1 knockdown (Figure 4E). Using RNA fluorescence in situ hybridization, we were also able to examine the colocalization of SMILR and CENPF with STAU1 knockdown (Figure 4F). This revealed that, when compared with control conditions, SMILR/CENPF transcript colocalization is not dependent on STAU1 expression and that there seems to be increased SMILR/CENPF colocalization events with STAU1 KD (Figure 4F). Collectively, these data suggest that once SMILR expression is upregulated in IL1-PDGF conditions, it is able to bind to CENPF mRNA. This may subsequently counteract STAU1-mediated regulation, thereby culminating in a proliferative environment and cell cycle progression in vSMCs.


## SMILR and the Targeted Cell Cycle Network Are Activated in Atherosclerosis and Ex Vivo Vein Model of Human Saphenous Vein

Despite context-dependent heterogeneity in vSMC pathobiology, defects in SMC cell cycle and hence proliferation, are hallmarks of vascular pathologies including atherosclerosis and neointimal hyperplasia associated with vein graft disease.<sup>34,9</sup> As SMILR is poorly conserved, we are limited to human disease and not animal models to study disease association and causality. To interrogate the SMILR:CENPF:STAU1 interaction in human atherosclerosis, we performed an RNA-seq on relatively stable and unstable regions dissected from fresh human carotid plaques obtained at carotid endarterectomy in symptomatic patients. Although classified as stable, these plaques may still contain regions of instability. This is demonstrated by ex vivo 18F-sodium fluoride imaging of explanted plaques, which was used to confirm the appropriate segregation by regions of relatively more unstable versus stable plaque, where increased uptake of the radiotracer<sup>35</sup> was more apparent in unstable dissections and less so in the stable regions (Figure 5A). Importantly, Principal Component Analysis of the RNA-seq showed a clear clustering of the distinct regions separately and not clustering together within each patient sample (Figure 5B). The differential expression analysis confirmed the changes of protein-coding genes linked with plaque instability, including those associated with inflammation, matrix remodeling, and calcification (Online Figure XII). SMILR expression was upregulated in all unstable plaque samples assessed by qRT-PCR (Figure 5C). Additionally, SMILR was detected using in situ hybridization with varying intensity across all carotid atherosclerotic plaques from symptomatic patients (Figure 5D, Online Figure XIII). STAU1 pulldowns in whole carotid plaques also further revealed an interaction with SMILR with a 2-fold enrichment compared with IgG controls ( $P < 0.01$ ; Figure 5E). Remarkably, we also observed that 32 of the 40 SMILR-dependent cell cycle interactome were also upregulated within the unstable plaques compared with stable, including CENPF (Figure 5F and 5G). Collectively, these data suggest that the SMILR/CENPF-STAU1 axis is activated in unstable atherosclerosis.

With arterial and venous SMCs differing significantly, we sought to further investigate the role of SMILR in relation to atherosclerosis by validating its mode of action in HCASMCs. First, we confirmed incorporation of EdU in HCASMCs stimulated with IL1-PDGF. This significantly upregulated proliferation, although as previously described (<sup>17</sup>, Figure 6A and 6B), the proliferative capacity of HCASMCs are significantly less than that observed in

**Figure 2 Continued. G,** Bar chart representing the % of total cells that were binucleated.  $*P < 0.05$ , Iman and Conover ranked nonparametric analysis followed by 1-way ANOVA vs IL (interleukin)-1 $\alpha$ /PDGF (platelet-derived growth factor)- $\beta\beta$  treatment alone (I+P);  $+ = P < 0.05$  vs siControls,  $n=3$  biological replicates. **H,** Bar chart representing caspase-3 activity in HSVSMCs cultured with siRNA or hydrogen peroxide as a positive control. Caspase activity measured by OD405.  $n=3$  biological replicates, vs I+P treatment. ns indicates not significant.





**Figure 3. RNA: RNA analysis reveal a SMILR: CENPF (centromere protein F) interaction.**

**A**, Schematic of DNA antisense biotinylated probes site for SMILR and GFP and the experimental design of RNA: RNA pull-downs. **B**, Bar charts representing relative enrichments of SMILR, CENPF, and MKI67 (marker of proliferation Ki-67) in SMILR-even and -odd pull-downs vs the GFP (green fluorescent protein) control pull-down. Each even and odd SMILR probe pull-down was performed once across 2 independent biological replicates. Effects of **(C)** SMILR knockdown and **(D)** SMILR overexpression on CENPF mRNA. \*\* $P < 0.05$  Iman and Conover nonparametric ranked analysis followed by Student *t* test,  $n = 3$  biological replicates. **E**, Representative fluorescence-activated cell sorter (FACS) histogram plots depicting EdU uptake in siCtrl and siCENPF treated humans saphenous vein derived smooth muscle cells (HSVSMCs). Gate represents EdU+ cells. **F**, Bar chart showing mean changes of EdU incorporation in siCtrl and siCENPF treated HSVSMCs. (Continued)

the HSVSMCs. Nevertheless, with IL1-PDGF induced proliferation in the HCASMCs, we also identified by qRT-PCR significant increases in SMILR, CENPF, MKI67, AURKB, and CDC20 transcripts (Figure 6C and 6D). Importantly and similar to that observed in the HSVSMCs, knockdown of SMILR and CENPF in HCASMCs (Online Figure XIV) resulted in reduction in proliferation (Figure 6E and 6F). Taken together, this suggests that although arterial and venous SMCs differ significantly, SMILR's mechanism of action remains consistent.

We also assessed the SMILR: CENPF axis in the context of vSMC proliferation associated with vein graft disease. Hereto, we used an ex vivo HSV model,<sup>36,37</sup> which is associated with time-dependent SMC proliferation, migration, and formation of neointima over 14 days in culture (Figure 7A).<sup>38</sup> We first validated this approach by monitoring EdU incorporation at 0, 7, and 14 days and found significant increases (Figure 7B and 7C). Thus, we hypothesized that SMILR expression may be regulated during the culture period. Accordingly, saphenous veins were cultured for 0, 7, or 14 days and the expression of SMILR, CENPF, and the downstream cell cycle-associated targets assessed by qRT-PCR. When compared with day 0 control, SMILR expression was increased  $28 \pm 13$ - ( $P < 0.05$ ) and  $53 \pm 19$ -fold ( $P < 0.01$ ), respectively, at day 7 and 14 (Figure 7D). We also identified a time-dependent increase in CENPF expression to  $8 \pm 1$ - ( $P < 0.05$ ) at day 7 and  $19 \pm 7$ -fold ( $P < 0.05$ ) at day 14 (Figure 7E). Similar to the qRT-PCR data obtained in Figure 6E, we are able to detect using immunohistochemistry increases in CENPF positive cells in the medial layer from 30% at day 0 to 51% at day 7 (Online Figure XV). Concordantly, expression of other SMILR downstream targets within the cell cycle network, namely AurKB, BUB1B, MKI67, and CDC20, were upregulated at day 7 ( $22 \pm 8$ -,  $11 \pm 3$ -,  $22 \pm 8$ -, and  $18 \pm 7$ -fold change, respectively) and day 14 ( $41 \pm 14$ -,  $34 \pm 14$ -,  $75 \pm 29$ -, and  $50 \pm 31$ -fold change, respectively; Online Figure XVI). Overall, these data suggest that SMILR expression and its downstream network has a strong association with pathological remodeling in human ex vivo vein grafts.

We then sought to manipulate SMILR expression in the ex vivo saphenous vein graft to assess the clinical relevance and therapeutic potential. We, therefore, used a novel siRNA approach within the clinically relevant time window of an initial 30 minutes (clinical window from harvesting of the saphenous vein to grafting) before culture in which to attempt to knockdown SMILR. Cy3-tagged siSMILR was first used to visualize the successful infiltration of the siRNA into the vein (Figure 7F). Because of the limitations of the longevity of siRNA chemistry,


by day 14 the siSMILR effects were found to be diminished (Online Figure XVII). In veins with siRNA intervention leading to a significant decrease in SMILR levels assessed at day 7 (Figure 7G), we also observed significant decreases in CENPF and MKI67 mRNA expression (Figure 7H and 7I). Finally, quantified proliferation by EdU incorporation in the cultured vein revealed a strong reduction from  $28.7 \pm 5.3\%$  EdU +ve/DAPI +ve nuclei in control conditions to  $5.2 \pm 2.6\%$  with SMILR knockdown (Figure 7J and 7K;  $P < 0.01$ ).

## DISCUSSION

Aberrant growth of vSMCs is a common and functionally important mechanism, which may ultimately contribute to the cause of numerous cardiovascular diseases.<sup>4</sup> Although the general mechanism of cell cycle regulation is well established,<sup>39</sup> cell-enriched regulators such as lncRNA are not at all well defined in terms of expression, association, and mechanism, which is crucial for the successful development of targeted therapeutics and improved knowledge of how the human transcriptome can impact physiological and pathological pathways. Here, we identify the mechanism and downstream network of the vSMC-enriched human lncRNA, SMILR, and demonstrate its therapeutic potential in the ex vivo HSV model (Figure 7). This has the potential to not only enhance our understanding of atherogenesis, neointimal hyperplasia, and plaque formation but also provides a clear therapeutic target for future investigation in a broad range of cardiovascular diseases.

The human genome contains a wide range of lncRNAs that are dynamically expressed in a temporal and cell-specific manner. These lncRNAs can influence the level and spatial distribution of many proteins and mRNAs to control key aspects of cellular function. lncRNAs have previously been shown to modulate cell cycle, primarily in cancer cell lines.<sup>40,41</sup> Additionally, lncRNAs, such as smooth muscle and endothelial cell-enriched migration/differentiation-associated lncRNA and myocardin-induced smooth muscle lncRNA, inducer of differentiation, have also been previously shown to be influential in cardiovascular diseases and essential in controlling the phenotypic switching of VSMCs to maintain their contractile phenotype<sup>(42,43)</sup>. More recently, the role of MEG3 (maternally expressed 3) in patients with pulmonary arterial hypertension was examined which revealed significantly reduced MEG3 expression levels in patients compared with healthy controls.<sup>44</sup> In vitro siRNA silencing of MEG3 resulted in increased SMC


**Figure 3 Continued.** Iman and Conover ranked nonparametric analysis followed by *t* test, *n*=3 biological replicates. \**P*<0.05. **G**, Fluorescent images of HSVSMCs stained with DAPI (4',6-diamidino-2-phenylindole) and phalloidin. Scale bar represents 50  $\mu$ m. Red arrows indicate binucleated cells. **H**, Bar chart representing the % of total cells that were binucleated. Iman and Conover ranked nonparametric analysis followed by Student *t* test \**P*<0.05 vs siCtrl, *n*=3 biological replicates. **I**, The effects of CENPF knockdown on mitotic associated genes compared to effects observed with knockdown of SMILR, \**P*<0.05, by Iman and Conover ranked nonparametric analysis followed by paired *t* test, *n*=4 biological replicates.



**Figure 4. STAU1 (Staufen 1) degrades the SMILR: CENPF (centromere protein F) interaction to mediate vascular smooth muscle cell (vSMC) proliferation.**

**A**, Schematic showing methodology of biotinylated SMILR pulldowns. **B**, Mass spectrometry identified 14-enriched SMILR-binding proteins. STAU1 was specifically enriched in the SMILR pulldown with 11-unique peptides detected. **C**, Anti-STAU1 pulldowns confirming interaction with SMILR and CENPF; \* $P < 0.05$ , by Iman and Conover ranked nonparametric analysis followed by  $t$  test,  $n = 3$  pulldowns from 3 independent patient samples. **D**, Relative quantification of STAU1, SMILR, and CENPF expression with siSTAU1 at 10 nmol/L. \* $P < 0.05$ , by Iman and Conover ranked nonparametric analysis followed by  $t$  test,  $n = 3$  biological replicates. **E**, The effects of STAU1 knockdown on the top 20 downregulated cell cycle-associated genes regulated by SMILR, \* $P < 0.05$ , by Iman and Conover ranked nonparametric analysis followed by  $t$  test,  $n = 3$  biological replicates. **F**, RNA fluorescence in situ hybridization (FISH) for SMILR (red) and CENPF (green) in stimulated vSMCs under control, siSMILR, siCENPF, and siSTAU1 conditions. Scale bar represents 20  $\mu\text{m}$ . Yellow arrows show some colocalization events.






**Figure 5. SMILR and the targeted cell cycle network are activated in atherosclerosis.**


**A**, Ex vivo  $^{18}\text{F}$  imaging of unstable vs stable plaques. **B**, Principal component analysis (PCA) of the RNA-sequencing (RNA-seq) of the stable and unstable samples. **C**, Relative FPKMs (fragments per kilobase of transcript per million mapped reads) of protein-coding genes linked with plaque instability, including those associated with inflammation and calcification. **D**, Representative images of in situ detection of SMILR in plaques obtained from the carotid artery derived from symptomatic patients at carotid endarterectomy ( $n=5$  biological replicates per plaque type, replicates in Online Figure XII). SMILR is visualized using NBT/BCIP (nitro-blue tetrazolium and 5-bromo-4-chloro-3'-indolylphosphate; purple) at varying intensities across plaques exhibiting either intraplaque hemorrhage or thick fibrous cap. Nuclei are stained with fast red. Scale bar represents 200  $\mu\text{m}$ . **E**, SMILR enrichment in STAU1 (Staufen 1) pulldowns in whole carotid plaques,  $n=6$ ,  $**P<0.01$ , by paired Student  $t$  test with paired experiments matched by color. Protein network (**F**) and heatmap (**G**) of the 34 proliferative and cell cycle-associated genes found to be dysregulated with SMILR manipulation and unregulated in unstable plaques. L indicates arterial lumen; and NC, lipid core.





**Figure 6. Role of SMILR in human coronary artery smooth muscle cells (HCASMCs).**

**A**, Representative fluorescence-activated cell sorter (FACS) histogram plots depicting EdU uptake in 0.2% and I+P treated HCASMCs. Gate represents EdU+ cells. **B**, Bar chart showing mean changes of EdU incorporation in 0.2% and I+P conditions. Iman and Conover ranked nonparametric analysis followed by *t* test,  $n=3$  biological replicates. \* $P<0.05$ . Bar charts showing relative expression of **(C)** SMILR and **(D)** CENPF (centromere protein F), MKI67 (marker of proliferation Ki-67), AURKB, and CDC20 by quantitative real-time polymerase chain reaction (qRT-PCR) in 0.2% and I+P stimulated HCASMCs. Iman and Conover ranked nonparametric analysis followed by *t* test,  $n=3$  biological replicates. \*\* $P<0.05$ . **E**, Representative FACS histogram plots depicting EdU uptake in siCtrl, siSMILR, and siCENPF treated HCASMCs. Gate represents EdU+ cells. **F**, Bar chart showing mean changes of EdU incorporation in siCtrl, siSMILR, and siCENPF treated cells. Iman and Conover ranked nonparametric analysis followed by *t* test,  $n=3$  biological replicates, \* $P<0.05$ .



**Figure 7. SMILR modulates the proliferation of the ex vivo human saphenous vein (HSV) organ culture.**

**A**, Graphical representation of ex vivo HSV proliferation model. **B**, Quantification of EdU +ve nuclei in the media of HSV in culture expressed as % of EdU +ve/DAPI (4',6-diamidino-2-phenylindole) +ve nuclei. **C**, Representative images of HSV in culture stained for EdU (green) and with DAPI (blue) at day 0, 7, and 14 (n=3 biological replicates per time point). **D** SMILR and **E** CENPF (centromere protein F) expression determined by quantitative real-time polymerase chain reaction (qRT-PCR) analysis at day 0, 7, and 14. **F**, Left: Graphical representation of the model of HSV siSMILR intervention; Right: Representative image of Cy3-labeled SMILR siRNA localization in HSV at 3 d post-siSMILR intervention; (Continued)

proliferation and migration while mechanistic investigation revealed that MEG3 regulates the p53 pathway in PASCs.<sup>45</sup> Although several lncRNAs have been identified that control key aspects of SMC and EC function, very little is known about their role in atherosclerosis. A key atherosclerotic lncRNA is ANRIL (antisense non-coding RNA in the INK4 locus), which was identified via genome-wide association studies, in which several SNPs (single nucleotide polymorphisms) located within this lncRNA were associated with atherosclerosis. It was later identified that ANRIL regulates gene expression epigenetically through recruiting repressive components of the polycomb complexes 1 and 2 to ANRIL-target gene promoters via Alu-repeats.<sup>46</sup>

Here, we showed that SMILR specifically targets the late mitotic pathway in proliferating HSVSMCs and interacts with CENPF mRNA and STAU1. Two recent studies have demonstrated that the lncRNAs, SNHG5 (small nucleolar RNA host gene 5), and TINCR (terminal differentiation-induced ncRNA), counteract STAU1-mediated decay to promote the stabilization of specific mRNAs to control tumor cell survival in colorectal cancer and somatic tissue differentiation, respectively.<sup>29,47</sup> Similar to TINCR and its target mRNA PGLYRP3 (peptidoglycan recognition protein 3), SMILR's interaction with CENPF mRNA appears to occur independent of STAU1 protein interaction as revealed by RNA fluorescence in situ hybridization. Although we see upregulation of both CENPF mRNA and SMILR with STAU1 knockdown, we cannot exclusively conclude whether STAU1's interaction with SMILR:CENPF mRNA is regulating CENPF at a post-transcriptional and post-translational stage. Additionally, STAU1 may not only affect the levels of CENPF at an RNA and protein levels but also regulate its sub-cellular localization since STAU1 has been found to be involved in mRNA transport and localization to mediate further translation.<sup>48</sup>

Whether the SMILR/CENPF interaction is dependent on base complementarity and/or secondary structure is a key future scientific question as the secondary structure of SMILR may be crucial for its localization, downstream interactions, and hence function.<sup>49–51</sup> Also, other mRNAs might be regulated by SMILR and STAU1 and sequencing of associated mRNAs may further provide a comprehensive network of interactions in proliferating vSMCs.

Consistent with our findings, previous studies have indicated that STAU1 primarily binds to protein-coding mRNAs of key mediators of cell cycle and that STAU1 expression and function necessarily fluctuates throughout

the cell cycle, being highest during the S-phase and rapidly decreasing during mitotic progression.<sup>34</sup> Additionally, STAU1 overexpression affects mitotic entry and impairs proliferation of transformed cells, therefore, highlighting STAU1-function must be inhibited in a temporally dependent manner during the cell cycle for proper mitotic progression.<sup>34</sup> With STAU1 being a ubiquitously expressed and a multifunctional protein, lncRNAs may be crucial for providing its cell-specific function and accordingly mediate cell-specific phenotypes. This may also be the case for CENPF, which is also ubiquitously expressed and shown to be multifunctional to control mitotic control, transcriptional regulation, and muscle cell differentiation.<sup>52</sup> Intriguingly, increased levels of CENPF have also been previously associated with increased proliferation in malignant conditions<sup>31</sup> and associated with a poor prognosis in human cancers.<sup>53,54</sup> However, the mechanism by which increased CENPF results in increased proliferation is not entirely understood. One possibility is that the role of CENPF in assembling kinetochore structures required for correct chromosome alignment and separation during mitosis is a rate-limiting step for mitotic progression. Taken together, our study, therefore, suggests that SMILR may provide such a critical cell-specific regulation of STAU1 and CENPF function in human vSMCs to trigger cell cycle progression and proliferation. Further studies are required to dissect mechanistically the consequence of CENPF mRNA regulation by SMILR. Particularly CENPF's mRNA stability, transport, and translation as well as the intersection of this with the mitotic phenotype that we observe when SMILR levels are reduced.

SMILR was previously suggested to function, at least in part, by regulating its neighboring gene, HAS2 (hyaluronan synthase 2),<sup>17</sup> although HAS2 is located ≈750 kb from SMILR. However, we showed using RNA-seq that HAS2 is downregulated with SMILR knockdown but was not affected by SMILR overexpression, confirming previous findings.<sup>17</sup> We also demonstrated the proliferative effects of SMILR occur in the cytoplasmic fraction since the siRNA approach used selectively blocked cytoplasmic SMILR expression and would, therefore, unlikely involve a direct targeting of the HAS2 gene in the nucleus. Here, we focused on the direct regulation by SMILR in the cytoplasm and find effects mediated by a distinct proliferative network, but we cannot rule out a downstream effect in the nucleus due to SMILR manipulation, or indeed a further proliferative effect mediated selectively in the nucleus by SMILR by an independent mechanism. In particular, we noticed the presence of

**Figure 7 Continued.** the section is costained with DAPI (blue) and for  $\alpha$ -smooth muscle actin ( $\alpha$ -SMA, green) at  $\times 60$  magnification. Relative quantification of (G) SMILR, (H) CENPF, and (I) MKI67 (marker of proliferation Ki-67) expression in HSV after siSMILR intervention at day 7 normalized to UBC (ubiquitin C). \* $P < 0.05$ , \*\* $P < 0.01$  by paired 2-tailed Student  $t$  test,  $n = 5$  biological replicates. J, Representative images of HSV post-siSMILR intervention stained for EdU (green) and with DAPI (blue). K, Mean  $\pm$  SEM of EdU +ve nuclei in the media of HSV after siSMILR intervention expressed as % of EdU +ve/DAPI +ve nuclei ( $n = 3$  biological replicates). Values are \* $P < 0.05$ ; vs siCtrl using Iman and Conover ranked nonparametric analysis followed by Student  $t$  test.

histone mRNAs among the dysregulated genes from the RNA-seq data. Although histone mRNAs are not within the list of SMILR predicted targets, the observed level change at the RNA level could lead to protein level changes and subsequent transcriptional changes.

The upregulation or downregulation of the SMILR-axis and its consequential effects on vSMC proliferation could influence numerous cardiovascular diseases. This was apparent in the ex vivo vein graft model in this study and suggests that this can influence neointimal hyperplasia and hence the long-term success of revascularisation of vein graft after coronary artery bypass surgery. Interestingly, we found a similar role for SMILR in HCASMCs and may, therefore, also be involved in atherosclerosis. However, targeting of SMILR may not be beneficial due to the potential reduction in stability and formation of a fibrous cap. Further studies are, however, required to fully understand the influence of the SMILR-axis with respect to SMC proliferation in the atherosclerotic environment and hence the susceptibility to plaque rupture and ultimately myocardial infarction and stroke.

Significantly, within a clinically amenable timeframe, siRNA-based gene therapy targeting SMILR is sufficient to markedly reduce proliferation in the ex vivo vein model. This excitingly provides a vSMC-specific target, which reduces the possibility of off-target effects in the remainder of the vessel wall, that is, inhibited re-endothelialization. This strongly suggests that such an intervention may reduce vein graft failure rates. Although our studies only show successful knockdown with siRNA for a limited time frame, whether this is sufficient to maintain a long-term antiproliferative effect is something that requires further studies. Nonetheless, other routes of SMILR-targeting gene therapy may be required for maximum longevity such as LNA-GapmeR antisense oligonucleotides.<sup>13</sup> However, antisense oligonucleotides target both nuclear and cytoplasmic fractions of a cell whereas siSMILR only has a cytoplasmic effect (Online Figure VI). Accordingly, the subsequent effects of antisense oligonucleotides knockdown of SMILR in the nuclear fraction must be studied to ensure no detrimental effects.

We demonstrate that SMILR is a vSMC-enriched lncRNA, essential in the control of cell cycle through binding of CENPF mRNA and STAU1. Our studies provide early but compelling evidence that SMILR is an exciting and novel target in the treatment of aberrant growth of vascular SMCs, with the potential to significantly reduce the rate of vein graft failure.

## ARTICLE INFORMATION

Received February 7, 2019; revision received July 5, 2019; accepted July 19, 2019.

## Affiliations

From the Queens Medical Research Institute, BHF Centre for Cardiovascular Sciences, University of Edinburgh, United Kingdom (A.D.M., M.D.B., V.M., K.P., J.H.,

J.P.S., J.I., J.K., A.S.T., N.L.M., D.E.N., A.C., J.C.S., J.R., A.H.B.); Institute of Cardiovascular and Medical Sciences, BHF Cardiovascular Research Centre, University of Glasgow, United Kingdom (A.C.B.); Institute of Molecular Cell and Systems Biology, College of Medicine, Veterinary and Life Sciences, University of Glasgow, United Kingdom (G.W.G.); School of Clinical Sciences, University of Bristol, Research Floor Level Seven, Bristol Royal Infirmary, United Kingdom (S.J.G.); Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel (I.U.); and Department of Pathology, Maastricht University Medical Center, the Netherlands (J.C.S., A.H.B.).

## Acknowledgments

We thank Lynne Maquat for her continued advice and to Gregor Aitchison and Yvonne Hancus for technical assistance. Flow cytometry data was generated with support from the QMRI Flow Cytometry and cell sorting facility, University of Edinburgh. We also thank the University of Edinburgh's CALM facility used for immunofluorescent microscopy. A.H. Baker, A.D. Mahmoud, M.D. Ballantyne, and J. Rodor designed experiments, interpreted data, and wrote the article. A.D. Mahmoud, M.D. Ballantyne, V. Miscianinov, K. Pinel, J. Hung, and J.P. Scanlon performed experiments. K. Pinel, J. Hung, J. Kaczynski, and A.S. Tavares sampled and conducted imaging on patient atherosclerotic plaques. J. Rodor did the RNA-sequencing (RNA-seq) analysis. I. Ulitsky provided pipeline for RNA-seq analysis. G.W. Gould provided guidance for the cell cycle studies. S.J. George provided guidance on ex vivo studies. N.L. Mills, D.E. Newby, and J.C. Sluimer provided guidance on atherosclerosis and clinical studies. A.C. Bradshaw and J.C. Sluimer provided samples for studies. All the authors discussed the data and edited the article.

## Sources of Funding

This work is supported by the British Heart Foundation (PG/16/51/32180 and RG/14/3/30706) and the University of Edinburgh's BHF Research Excellence Award (RE/13/3/30183). A.H. Baker is supported by the British Heart Foundation Chair of Translational Cardiovascular Sciences (CH/11/2/28733) and European Research Council (EC 338991 VASCMIR).

## Disclosures

None.

## REFERENCES

- Patel MI, Ghosh P, Melrose J, Appleberg M. Smooth muscle cell migration and proliferation is enhanced in abdominal aortic aneurysms. *Aust N Z J Surg*. 1996;66:305–308. doi: 10.1111/j.1445-2197.1996.tb01192.x
- Marx SO, Totary-Jain H, Marks AR. Vascular smooth muscle cell proliferation in restenosis. *Circ Cardiovasc Interv*. 2011;4:104–111. doi: 10.1161/CIRCINTERVENTIONS.110.957332
- Sallam T, Sandhu J, Tontonoz P. Long noncoding RNA discovery in cardiovascular disease: decoding form to function. *Circ Res*. 2018;122:155–166. doi: 10.1161/CIRCRESAHA.117.311802
- Bochaton-Piallat ML, Bäck M. Novel concepts for the role of smooth muscle cells in vascular disease: towards a new smooth muscle cell classification. *Cardiovasc Res*. 2018;114:477–480. doi: 10.1093/cvr/cvy031
- Daemen J, Serruys PW. Drug-eluting stent update 2007: part I. A survey of current and future generation drug-eluting stents: meaningful advances or more of the same? *Circulation*. 2007;116:316–328. doi: 10.1161/CIRCULATIONAHA.106.621342
- Roopmani P, Sethuraman S, Satheesh S, Maheswari Krishnan U. The metamorphosis of vascular stents: passive structures to smart devices. *RSC Advances*. 2016;6:2835s–2853s
- Brancati MF, Burzotta F, Trani C, Leonzi O, Cuccia C, Crea F. Coronary stents and vascular response to implantation: literature review. *Pragmat Obs Res*. 2017;8:137–148. doi: 10.2147/POR.S132439
- Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. *Nature*. 2011;473:317–325. doi: 10.1038/nature10146
- Gomez D, Owens GK. Smooth muscle cell phenotypic switching in atherosclerosis. *Cardiovasc Res*. 2012;95:156–164. doi: 10.1093/cvr/cvs115
- Uchida S, Dimmeler S. Long noncoding RNAs in cardiovascular diseases. *Circ Res*. 2015;116:737–750. doi: 10.1161/CIRCRESAHA.116.302521
- Anastasiadou E, Jacob LS, Slack FJ. Non-coding RNA networks in cancer. *Nat Rev Cancer*. 2018;18:5–18. doi: 10.1038/nrc.2017.99
- Aune TM, Crooke PS III, Patrick AE, Tossberg JT, Olsen NJ, Spurlock CF III. Expression of long non-coding RNAs in autoimmunity and linkage to



- enhancer function and autoimmune disease risk genetic variants. *J Autoimmun.* 2017;81:99–109. doi: 10.1016/j.jaut.2017.03.014
13. Micheletti R, Plaisance I, Abraham BJ, Sarre A, Ting CC, Alexanian M, Maric D, Maisson D, Nemir M, Young RA, et al. The long noncoding RNA Wisper controls cardiac fibrosis and remodeling. *Sci Transl Med.* 2017;9:eaa19118.
  14. Ulitsky I, Bartel DP. lincRNAs: genomics, evolution, and mechanisms. *Cell.* 2013;154:26–46. doi: 10.1016/j.cell.2013.06.020
  15. Rashid F, Shah A, Shan G. Long Non-coding RNAs in the cytoplasm. *Genomics Proteomics Bioinformatics.* 2016;14:73–80. doi: 10.1016/j.gpb.2016.03.005
  16. Barra J, Leucci E. Probing long non-coding RNA-protein interactions. *Front Mol Biosci.* 2017;4:45. doi: 10.3389/fmolb.2017.00045
  17. Ballantyne MD, Pinel K, Dakin R, Vesey AT, Diver L, Mackenzie R, Garcia R, Welsh P, Sattar N, Hamilton G, et al. Smooth Muscle Enriched Long Noncoding RNA (SMILR) regulates cell proliferation. *Circulation.* 2016;133:2050–2065. doi: 10.1161/CIRCULATIONAHA.115.021019
  18. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods.* 2001;25:402–408. doi: 10.1006/meth.2001.1262
  19. Goto H, Yasui Y, Kawajiri A, Nigg EA, Terada Y, Tatsuka M, Nagata K, Inagaki M. Aurora-B regulates the cleavage furrow-specific vimentin phosphorylation in the cytokinetic process. *J Biol Chem.* 2003;278:8526–8530. doi: 10.1074/jbc.M210892200
  20. Goldenson B, Crispino JD. The aurora kinases in cell cycle and leukemia. *Oncogene.* 2015;34:537–545. doi: 10.1038/onc.2014.14
  21. Zhang Y, Chen D, Smith MA, Zhang B, Pan X. Selection of reliable reference genes in *Caenorhabditis elegans* for analysis of nanotoxicity. *PLoS One.* 2012;7:e31849. doi: 10.1371/journal.pone.0031849
  22. Gu SX, Li X, Hamilton JL, Chee A, Kc R, Chen D, An HS, Kim JS, Oh CD, Ma YZ, et al. MicroRNA-146a reduces IL-1 dependent inflammatory responses in the intervertebral disc. *Gene.* 2015;555:80–87. doi: 10.1016/j.gene.2014.10.024
  23. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF- $\kappa$ B-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. *Proc Natl Acad Sci USA.* 2006;103:12481–12486.
  24. Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. *Nucleic Acids Res.* 2017;45:D362–D368. doi: 10.1093/nar/gkw937
  25. Zielke N, Edgar BA. FUCCI sensors: powerful new tools for analysis of cell proliferation. *Wiley Interdiscip Rev Dev Biol.* 2015;4:469–487. doi: 10.1002/wdev.189
  26. Terada Y. Role of chromosomal passenger complex in chromosome segregation and cytokinesis. *Cell Struct Funct.* 2001;26:653–657.
  27. Terai G, Iwakiri J, Kameda T, Hamada M, Asai K. Comprehensive prediction of lncRNA-RNA interactions in human transcriptome. *BMC Genomics.* 2016;17(suppl 1):12. doi: 10.1186/s12864-015-2307-5
  28. Engreitz JM, Pandya-Jones A, McDonel P, Shishkin A, Sirokman K, Surka C, Kadri S, Xing J, Goren A, Lander ES, et al. The Xist lncRNA exploits three-dimensional genome architecture to spread across the X chromosome. *Science.* 2013;341:1237973. doi: 10.1126/science.1237973
  29. Kretz M, Siprashvili Z, Chu C, Webster DE, Zehnder A, Qu K, Lee CS, Flockhart RJ, Groff AF, Chow J, et al. Control of somatic tissue differentiation by the long non-coding RNA TINCR. *Nature.* 2013;493:231–235. doi: 10.1038/nature11661
  30. Bomont P, Maddox P, Shah JV, Desai AB, Cleveland DW. Unstable microtubule capture at kinetochores depleted of the centromere-associated protein CENP-F. *EMBO J.* 2005;24:3927–3939. doi: 10.1038/sj.emboj.7600848
  31. Holt SV, Vergnolle MA, Hussein D, Wozniak MJ, Allan VJ, Taylor SS. Silencing Cenp-F weakens centromeric cohesion, prevents chromosome alignment and activates the spindle checkpoint. *J Cell Sci.* 2005;118:4889–4900. doi: 10.1242/jcs.02614
  32. Guil S, Esteller M. RNA-RNA interactions in gene regulation: the coding and noncoding players. *Trends Biochem Sci.* 2015;40:248–256. doi: 10.1016/j.tibs.2015.03.001
  33. Gong C, Maquat LE. lncRNAs transactivate STAU1-mediated mRNA decay by duplexing with 3' UTRs via Alu elements. *Nature.* 2011;470:284–288. doi: 10.1038/nature09701
  34. Boulay K, Ghram M, Viranaicken W, Trépanier V, Mollet S, Fréchina C, DesGroseillers L. Cell cycle-dependent regulation of the RNA-binding protein Staufen1. *Nucleic Acids Res.* 2014;42:7867–7883. doi: 10.1093/nar/gku506
  35. Joshi NV, Vesey AT, Williams MC, Shah ASV, Calvert PA, Craighead FHM, Yeoh SE, Wallace W, Salter D, Fletcher AM, et al. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial. *Lancet.* 2014;383:705–713. doi: 10.1016/S0140-6736(13)61754-7
  36. Soyombo AA, Angelini GD, Bryan AJ, Jasani B, Newby AC. Intimal proliferation in an organ culture of human saphenous vein. *Am J Pathol.* 1990;137:1401–1410.
  37. Angelini GD, Soyombo AA, Newby AC. Winner of the ESVS prize 1990. Smooth muscle cell proliferation in response to injury in an organ culture of human saphenous vein. *Eur J Vasc Surg.* 1991;5:5–12.
  38. George SJ, Johnson JL, Angelini GD, Newby AC, Baker AH. Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration and neointimal formation in human saphenous vein. *Hum Gene Ther.* 1998;9:867–877. doi: 10.1089/hum.1998.9.6-867
  39. Musacchio A, Salmon ED. The spindle-assembly checkpoint in space and time. *Nat Rev Mol Cell Biol.* 2007;8:379–393.
  40. Nötold L, Frank L, Gandhi M, Polycarpou-Schwarz M, Groß M, Gunkel M, Beil N, Erfle H, Harder N, Rohr K, et al. The long non-coding RNA LINC00152 is essential for cell cycle progression through mitosis in HeLa cells. *Sci Rep.* 2017;7:2265. doi: 10.1038/s41598-017-02357-0
  41. Hu WL, Jin L, Xu A, Wang YF, Thorne RF, Zhang XD, Wu M. GUARDIN is a p53-responsive long non-coding RNA that is essential for genomic stability. *Nat Cell Biol.* 2018;20:492–502. doi: 10.1038/s41566-018-0066-7
  42. Lyu Q, Xu S, Lyu Y, Choi M, Christie CK, Slivano OJ, Rahman A, Jin ZG, Long X, Xu Y, et al. SENCER stabilizes vascular endothelial cell adherens junctions through interaction with CKAP4. *Proc Natl Acad Sci USA.* 2019;116:546–555.
  43. Zhao J, Zhang W, Lin M, Wu W, Jiang P, Tou E, Xue M, Richards A, Jourdeuil D, Asif A, et al. MYOSLID is a novel serum response factor-dependent long noncoding RNA that amplifies the vascular smooth muscle differentiation program. *Arterioscler Thromb Vasc Biol.* 2016;36:2088–2099. doi: 10.1161/ATVBAHA.116.307879
  44. Sun Z, Nie X, Sun S, Dong S, Yuan C, Li Y, Xiao B, Jie D, Liu Y. Long non-coding RNA MEG3 downregulation triggers human pulmonary artery smooth muscle cell proliferation and migration via the p53 signaling pathway. *Cell Physiol Biochem.* 2017;42:2569–2581. doi: 10.1159/000480218
  45. Jaé N, Heumüller AW, Fouani Y, Dimmeler S. Long non-coding RNAs in vascular biology and disease. *Vascul Pharmacol.* 2019;114:13–22. doi: 10.1016/j.vph.2018.03.003
  46. Holdt LM, Hoffmann S, Sass K, Langenberger D, Scholz M, Krohn K, Finstermeier K, Stahringer A, Wilfert W, Beutner F, et al. Alu elements in ANRIL non-coding RNA at chromosome 9p21 modulate atherogenic cell functions through trans-regulation of gene networks. *PLoS Genet.* 2013;9:e1003588. doi: 10.1371/journal.pgen.1003588
  47. Damas ND, Marcatti M, Côme C, Christensen LL, Nielsen MM, Baumgartner R, Gylling HM, Maglieri G, Rundsten CF, Seemann SE, et al. SNHG5 promotes colorectal cancer cell survival by counteracting STAU1-mediated mRNA destabilization. *Nat Commun.* 2016;7:13875. doi: 10.1038/ncomms13875
  48. Park E, Maquat LE. Staufen-mediated mRNA decay. *Wiley Interdiscip Rev RNA.* 2013;4:423–435. doi: 10.1002/wrna.1168
  49. Brown JA, Valenstein ML, Yario TA, Tycowski KT, Steitz JA. Formation of triple-helical structures by the 3'-end sequences of MALAT1 and MEN $\beta$  noncoding RNAs. *Proc Natl Acad Sci USA.* 2012;109:19202–19207. doi: 10.1073/pnas.1217338109
  50. Novikova IV, Hennelly SP, Sanbonmatsu KY. Sizing up long non-coding RNAs: do lncRNAs have secondary and tertiary structure? *Bioarchitecture.* 2012;2:189–199. doi: 10.4161/bioa.22592
  51. Somarowthu S, Legiewicz M, Chillón I, Marcia M, Liu F, Pyle AM. HOTAIR forms an intricate and modular secondary structure. *Mol Cell.* 2015;58:353–361. doi: 10.1016/j.molcel.2015.03.006
  52. Ma L, Zhao X, Zhu X. Mitosin/CENP-F in mitosis, transcriptional control, and differentiation. *J Biomed Sci.* 2006;13:205–213. doi: 10.1007/s11373-005-9057-3
  53. Zhuo YJ, Xi M, Wan YP, Hua W, Liu YL, Wan S, Zhou YL, Luo HW, Wu SL, Zhong WD, et al. Enhanced expression of centromere protein F predicts clinical progression and prognosis in patients with prostate cancer. *Int J Mol Med.* 2015;35:966–972. doi: 10.3892/ijmm.2015.2086
  54. O'Brien SL, Fagan A, Fox EJ, Millikan RC, Culhane AC, Brennan DJ, McCann AH, Hegarty S, Moyna S, Duffy MJ, Higgins DG, et al. CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer. *Int J Cancer.* 2007;120:1434–1443. doi: 10.1002/ijc.22413